Coordinatore | ALBERT-LUDWIGS-UNIVERSITAET FREIBURG
Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie. |
Nazionalità Coordinatore | Germany [DE] |
Totale costo | 164˙162 € |
EC contributo | 149˙194 € |
Programma | FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
Code Call | ERC-2012-PoC |
Funding Scheme | CSA-SA(POC) |
Anno di inizio | 2012 |
Periodo (anno-mese-giorno) | 2012-11-01 - 2013-10-31 |
# | ||||
---|---|---|---|---|
1 |
ALBERT-LUDWIGS-UNIVERSITAET FREIBURG
Organization address
address: FAHNENBERGPLATZ contact info |
DE (FREIBURG) | hostInstitution | 149˙194.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'Vaccinations are a highly efficient and effective means for protecting humans and animals against severe diseases. For reaching an initial protective immune response, the vaccine must repeatedly be administered, mainly by injection. Omitting the repeated vaccine injections either due to the unavailability of medical personnel (mainly in developing countries) or due to negligence results in insufficient protection and susceptibility to disease. One solution for overcoming this lack in protection would be a vaccination strategy avoiding the need for additional appointments with medical personnel. This could be realized by the use of a vaccine depot that is injected together with the first vaccine dose. At a preset time point the patient would simply swallow a pill containing a trigger substance that would subsequently induce the release of the vaccine from the depot and induce the subsequent protection of the patient. In this project we will perform the proof of concept for the functionality of such a depot in animal models using vaccines against widespread infectious diseases like hepatitis B or human papilloma virus. With this study we aim at demonstrating the proof of concept that our newly developed materials can be applied to increase the patient compliance of vaccinations and thereby to increase the vaccination success rate. As our approach is likely generically applicable to different vaccines, we anticipate a highly attractive economical potential in the human medical and the veterinary fields. The scientific data obtained in this project together with a comprehensive market research and the development of a business strategy will shape a highly attractive commercial proposition for the successful valorization of our current ERC-funded research.'
Development of chemical biology tools for the elucidation of protein phosphatase-1 substrates and druggability
Read More